This study investigates GABA B protein expression and mRNA levels in three types of specimens. Two types of specimens from patients with temporal lobe epilepsy (TLE), secondary to hippocampal sclerosis, sclerotic hippocampal samples (TLE-HS), and tissue from the structurally preserved non-spiking ipsilateral superior temporal gyrus (TLE-STG) removed from the same patient during epilepsy surgery; and third specimen is hippocampal tissue from individuals with no history of epilepsy (post-mortem controls, PMC).
Introduction
The main inhibitory neurotransmitter in the mammalian central nervous system (CNS), g-aminobutyric acid (GABA), plays important roles in regulating neuronal activity, plasticity, and pathophysiology. Its action is mediated through distinct receptor types: ionotropic (GABA A and GABA C ) and metabotropic (GABA B ). Both GABA A and GABA B receptors have been implicated in many important physiological functions and pathological conditions in the brain (Gassmann and Bettler, 2012; Castelli and Gessa, 2016) , such as absence seizures (Stewart et al., 2009) .
GABA B receptors have been demonstrated at both pre-and postsynaptic sites of both excitatory and inhibitory neurones (Chen et al., 2004) . Presynaptic receptor stimulation reduces the evoked release of GABA and other neurotransmitters, whereas postsynaptic GABA B receptor activation increases neuronal K þ conductance to generate long-lasting inhibitory postsynaptic potentials (IPSPs). Along with other findings, previous pharmacological and physiological studies have suggested the existence of two distinct GABA B1 receptor subtypes at pre-and postsynaptic sites and in different cells types and brain structures (Bowery, 1997; Deisz et al., 1997; Dutar and Nicoll, 1988; Pitler and Alger, 1994) . The evidence for two different GABA B1 receptor isoforms (GABA B1a and GABA B1b ) was first characterised by Kaupmann et al. (1997) . A second subunit was subsequently characterised (Kaupmann et al., 1997; Jones et al., 1998; White et al., 1998) .
The distribution of GABA B1 receptors in human hippocampus has been demonstrated with receptor binding autoradiography (Princivalle et al., 2002) . Expression of GABA B1 mRNA in the rat CNS, human hippocampus and spinal cord has been established by radiolabelled riboprobes recognising the two GABA B1 mRNA variants (Kaupmann et al., 1997; Benke et al., 1999; Liang et al., 2000; Towers et al., 2000) . The expression of GABA B2 messengers has also been described widely expressed in rat brain (Clark et al., 2000; Calver et al., 2000) . In addition GABA B1 (a/b) and GABA B2 immunoreactivity has been demonstrated in the rat CNS Princivalle et al., 2000a Princivalle et al., , 2000b Charles et al., 2001) . Nevertheless, it is still unclear how the two GABA B1 variants and the GABA B2 mature proteins are distributed in different neuronal regions and cell types in human brain tissue such as the hippocampus, or how the transcription of GABA B1 and GABA B2 may be affected by pathological states such as epilepsy.
Temporal lobe epilepsy (TLE) is the commonest and most researched drug-refractory focal epilepsy. Electrophysiological evidence has demonstrated that there is a lack of inhibition in TLE due to the abolished slow component of GABA B receptor-mediated IPSPs (Mangan and Lothman, 1996; Teichgr€ aber et al., 2009 ). In addition, there is pharmacological and physiological evidence that GABA B receptor is impaired in animal models of TLE (Chandler et al., 2003; Fürtinger et al., 2003a ; Mare s and Kubov a, 2015; Leung et al., 2016) . However, the localization and quantitative expression of GABA B isoforms and subunits have not yet been elucidated in animal models or in human TLE.
Previous studies reported impaired GABA B receptor mediated currents in TLE (Straessle et al., 2003; Rocha et al., 2015) . This study aimed to examine possible differences in GABA B1a, GABA B1b and GABA B2 mRNA and protein expression. We investigated whether GABA B protein expression showed a reduction in the hippocampal tissue of patients with mesial temporal sclerosis (TLE-HS) compared to tissue taken from the same patients' superior temporal gyrus (TLE-STG) and post-mortem hippocampal control (PMC) tissue from individuals with no history of epilepsy.
Materials and methods

Patient tissue collection and clinical data
The majority of surgical samples were obtained from the Royal Hallamshire Hospital (R&D approval STH15210). The post-mortem immunohistochemistry samples were obtained from The National Hospital for Neurology and Neurosurgery. All samples were obtained with the understanding and the written consent of each patient. The sample collection procedure fully conformed with the Code of Ethics of the World Medical Association (Declaration of Helsinki), British Medical Journal (1964) , and the Institute of Neurology Joint Research Ethics Committee [Ethics Committee Protocol Pro-Forma (January 1998)]. The study was approved by the South Yorkshire Research Ethics Committee (08/H1310/49).
The surgical sclerotic human hippocampal tissue (TLE-HS) and non-sclerotic (TLE-STG) samples were obtained from the same patient with medically refractory TLE, undergoing surgical resection. Only patients with TLE secondary to unilateral hippocampal sclerosis were included. Clinical and demographic information about these patients is in Table 1 . The excision of the samples was based on pre-surgical clinical evaluation including interictal and ictal EEG studies and magnetic resonance imaging (MRI) in all cases. Each sample was divided into two parts, one part was snap frozen (Kingsbury et al., 1996) and stored at À80 C until RNA and protein extraction were performed. All pre-operative diagnoses of HS were confirmed after surgery by histopathological examination based on established diagnostic criteria . The second part of the sample was fixed as previously described : briefly they were post-fixed in 4% paraformaldehyde, then dehydrated through ethanol at increasing concentration, paraffin-embedded overnight, sliced by vibratome at 10 mm, mounted on slides, dried and stored at R.T. until use for histopathological analysis and immunohistochemistry experiments. The TLE-STG specimens were taken from the superior temporal gyri which looked structurally preserved on MRI, and had not been shown to generate ictal or inter-ictal epileptiform activity during pre-surgical electroencephalographic monitoring. If this kind of samples does not follow the above criteria they were not collected.
The flash-frozen post-mortem hippocampal samples were obtained from the UCL Brain Bank (08/H0718/54). They were from individuals with no previous medical history of neurological or psychiatric disease (Table 2) . At autopsy the hippocampi were dissected, pH was checked to be between 6 and 7, and the samples were flash frozen and stored at À80 C.
Quantitative real-time polymerase chain reaction (qRT-PCR)
RNA extraction
The total RNA was extracted from samples using SV Total RNA Isolation System kit according to manufacturer's instructions (Promega). Briefly, the hippocampal tissue lysates were prepared by adding 1 ml RNA lysis buffer to 342 mg of tissue weight. The tissue lysates were diluted with SV RNA dilution buffer and RNA was then adsorbed to a silica membrane-based column where it was purified by a spin method. RNA was subjected to DNase treatment, washed and eluted with 100 ml of Nuclease-free water.
The RNA purity was checked by the NanoDrop-1000 spectrophotometer, and the RNA integrity was checked by 1% agarose gel electrophoresis.
cDNA synthesis
Complementary DNA (cDNA) was synthesised by using the Superscrpit III first strand synthesis system (Life Technologies, 18080-051) according to the manufacturer's recommendation.
Starting from 1 mg of total RNA, cDNA was synthesised by using 50 mM of oligo (dT) 20 primer, 40 U of RNaseOUT and 200 U of Superscrpit III reverse transcriptase enzyme. The cDNA was then purified by using QIAquick PCR purification kit (Qiagen, 28104) and quantified with the NanoDrop-1000 spectrophotometer.
qRT-PCR
The mRNA expression of GABA B1 and GABA B2 subunits was investigated by qRT-PCR in 26 TLE-HS and 11 TLE-STG specimens (Table 1 ) and 10 post-mortem samples ( Table 2 ). The qRT-PCR was performed on a StepOnePlus™ Real-Time PCR System (Applied Biosystems) using TaqMan gene expression assays (Table 3) . A 10 ml volume of PCR reaction mix was prepared by combining template cDNA sample, TaqMan Universal PCR Master Mix (Applied Biosystems, 4352042) and TaqMan gene expression assays (Life Technologies). Cyclophilin A (PPIA) and cyclin-dependent kinase inhibitor 1B (CDKN1B) were selected as reference genes for our study as they were among the most stably expressed genes in TLE (Wierschke et al., 2010) . Results were analysed using the 2 eDCt method and presented as relative gene expression normalized to the average threshold cycle of the two housekeeping genes.
Quantitative two colour Western blot (qWB)
Protein extraction and quantification
The hippocampi tissues were homogenised at 4 C in CelLytic™ (C3228, Sigma) and protease inhibitor cocktail (P8340, Sigma). The lysate was centrifuged twice at 500 XG for 15 min at 4 C. The supernatant was centrifuged at 20,000 XG for 40 min at 4 C and pellet was suspended in 50 mM TrisHCl buffer pH 7.5 (TBS). The total protein was then quantified by Bicinchoninic acid protein assay kit according to the manufacturer's protocol (BCA1, B9643, Sigma-Aldrich). Table 2 shows post-mortem samples' features. 
Quantitative WB
The GABA B receptor subunits were investigated by qWB in 9 TLE-HS, 6 TLE-STG, and 4 PMC samples (according to sample availability). 20 mg of protein was loaded on 8% sodium dodecyl sulphate-polyacrylamide gel for electrophoresis (SDS-PAGE). The separated proteins were electro-transferred onto a nitrocellulose membrane, which was washed briefly in phosphate buffered saline (PBS) for few minutes. The membranes were then blocked with 5% w/v non-fat dry milk (NFDM) in PBS and 0.1% Tween 20 (PBST) for 1 h at room temperature (RT). Then they were incubated with primary diluted antibodies (Table 4 ) over night at 4 C with gentle shaking. A generous amount of 0.1% PBST buffer was used to wash the membranes 4 times for 5 min each. Then membranes were incubated with infrared-labelled secondary antibodies for 1 h at RT followed by 4 washes with 1X PBS for 5 min each. The membranes were scanned on an Odyssey infrared imaging system (LI-COR, Biosciences, NE, U.S.A.). The 700 nm and 800 nm channel scanning intensities were set to 4 and 6 respectively. The images acquired were quantified on the Odyssey software (version 1.2) according to the software manual and Picariello et al. (2006) . GABA B1(a-b) , and GABA B2 bands intensities were normalized to b-actin to eliminate any loading variation.
Immunohistochemistry (IHC)
Brain sections preparation
Sections (10 mm) of paraffin-embedded human hippocampal tissue were cut by a microtome, mounted onto charged microscope slides (BDH Superfrost Plus) and stored with desiccant in plastic slide boxes at RT until required.
Tissue pre-treatment and application of antibodies
The immunohistochemistry antibodies sub-types specificity to human GABA B1a , GABA B1b or GABA B2 was previously tested (Calver et al., 2000) . Immunohistochemistry (IHC) was conducted on 7 TLE-HS (Table 1) and 5 PMC specimens (Table 2) according to specimen availability. Following antigen retrieval, sections were rinsed in PBS, endogenous peroxidase activity blocked by incubation with hydrogen peroxide (0.3% in PBS) for 30 min, and followed by a rinse in fresh PBS. Sections were then incubated with normal goat serum (NGS) (1:10 in PBS) for 75 min, and subsequently overnight at 4 C with the primary antibodies (Table 4) respectively in PBS containing 1% NGS.
Following incubation with primary antibodies, the sections were washed with fresh PBS for 1 h then incubated with secondary biotinylated antibodies (Table 4) for 75 min, rinsed for 1 h in PBS and incubated with the avidin-biotin peroxidase complex (ABC; Vector) for 75 min. Peroxidase staining was performed by incubating the sections in 0.002% 3.3 0 diaminobenzidine and 0.002% H 2 O 2 in 50 mM Tris buffer, pH 7.6. The sections were dehydrated, and cover-slipped with diethyl-pyro carbonate (DPX).
Microscope visualization and quantitative IHC (qIHC)
Neuronal counting was performed as before using a stereological method as previously described (Princivalle et al., 2002 . The number and intensity of GABA B receptor subunits were quantified in pyramidal and granular cells in TLE-HS and PMC IHC sections using the Q-Capture Pro 7™ (QCapture 10, 2010) connected to an Olympus BX60 microscope. In order to quantify the immunosignals of the GABA B1 receptor isoforms and subunit, 13 sections from TLE patients and 5 from PMC were analysed. The microscope amplification used for quantification of each slide was 10 (ocular lens) Â 20 (objective lens), giving a total amplification of 200Â. For each slide 6 images of the area of interest (hippocampus) were captured. The raw relative optical density (ROD) of GABA B immunosignals was determined using the measuring tools of Q-Capture Pro 7™ software. The pyramidal cells were marked with a yellow triangle and granular cells with a blue square measuring tool. The ROD was normalized by subtracting the background (calculated by averaging 10 background spots in each slide). To correct for neuronal loss, ROD per neuron was calculated by dividing the total ROD on the number of GABA B immunopositive neurons and excluding glial cells.
Statistical analysis
The GraphPad Prism 6 software for Windows, version 6.05 was used for the statistical analysis (San Diego, CA, USA; www. graphpad.com). The Shapiro-Wilk W test was performed to test the normality of the data. The simple linear regression was used to do the correlation analysis. The Kruskal-Wallis with ConoverInman post hoc analysis test was used, for any experiment, to identify significant differences between samples (*P 0.05, **P < 0.01, ***P < 0.001). Data presented as median and interquartile range values.
Results
In this study we have investigated the expression of GABAB receptor subunit transcripts and proteins in human samples of TLE-HS, TLE-STG, and PMC. The median age of TLE-HS patients was 38 years (range 22e63). Patients had had epilepsy for a median of 23 years prior to surgery (range 2e53). Patients were taking a median of 3 antiepileptic drugs at the time of surgery. The patients had simple or complex partial seizures and 36% of them had also generalised tonic clonic seizures. 26% of patients had a history of febrile seizures. Only 14 from 23 patients (60%) of patients were seizure free after 1 year of epileptic surgery. 
qRT-PCR
The correlation between PMC mRNA samples versus age and post-mortem interval in demonstrates no correlation between the mRNA findings and these factors that could have influence the mRNA expression (supplementary material). The data from qRT-PCR, obtained from the whole resected hippocampi, show a very similar trend for both GABA B1 and GABA B2 subunits. The comparison of TLE-HS and the PMC samples reveals no difference in GABA B1 subunit expression between the groups, but possibly an increased GABA B2 expression in the TLE-HS tissue. In contrast, the comparison of TLE-HS with the TLE-STG samples showed a statistically significant lower level of expression of GABA B2 in the TLE-HS tissue (see Fig. 1 ). Fig. 2A shows a double-labelled Western blot image demonstrate a fairly consistent level of b-actin expression in the three study groups. However, there is a clear gradient of the expression of all three GABA B variants across the study groups. These proteins are expressed most strongly in TLE-STG, less strongly in TLE-HS and least strongly in PMC tissue. The data obtained by quantitative double-labelled analysis (Fig. 2B) follows the same trend although differences between the TLE-HS and the TLE-STG comparisons were only significant for GABA B2 . Comparing TLE-HS to PMC, statistically significant up regulation was observed for GABA B1a , GABA B1b, and GABA B2 .
Qualitative and quantitative WB
Distribution and comparison of GABA B receptor protein immunoreactivity in PMC and TLE-HS hippocampi
GABA B1a , GABA B1b and GABA B2 receptor proteins appeared to have a similar location in the TLE-HS and PMC hippocampal sections; furthermore, no evidence of single subunit labelling was observed in the hippocampal subregions of either sample category (Fig. 3AeF) . In PMC cases GABA B2 and GABA B1b exhibited the highest and the lowest immunoexpression respectively. All the three proteins displayed the highest expression in the dentate gyrus (DG) followed by the different cornu ammonis (CA) areas (all with comparable immunointensity), and the subiculum, which showed the lowest level of immunopositivity. Whereas immunopositivity to GABA B1 was greater in pyramidal PMC than TLE-HS cells it was lower in granular PMC than TLE-HS cells. In contrast, GABA B2 immunopositivity was more marked in TLE-HS than PMC in both types of neurons. Fig. 4D and E shows semi-quantitative immunosignal measurements demonstrating the intensity of immunopositivity per remaining neuron in PMC and TLE-HS. The GABA B2 signal intensity is higher while GABA B1a is lower in TLE-HS patients compared to PMC in both pyramidal and granular cells. The comparison of GABA B1b intensity between TLE-HS and PMC cells on the other hand showed higher GABA B1b intensity in granular and lower intensity in pyramidal cells (resulting not only from the image shown but from the averaged analysis of 5 patients); however, these differences did not achieve significance in the small number of samples available for comparison.
Figs. 5 and 6 show how representative pyramidal cells in CA areas and DG granular neurones reacted with the three antibodies for GABA B1a , GABA B1b and GABA B2 at higher magnification. The immunosignal proved to be specific for all three antibodies. The left panel in Fig. 5 represents pyramidal neurones in of CA1. The immunoreactivity was mainly expressed by the cell bodies and apical dendrites; there was no nuclear staining at all, either in PMC or in the TLE-HS sections. The main difference between PMC and TLE-HS CA1 was the intensity of immunoreactivity in most of the neuronal cells. GABA B1a and GABA B2 immunoreactivity appeared Kruskal-Wallis with Conover-Inman post hoc analysis test was used to identify significant differences between (*P 0.05, **P < 0.01, ***P < 0.001). Data presented as median and interquartile range values. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) stronger in a few neurones, whilst the GABA B1b immunosignal seemed fainter in the majority of TLE-HS compared to PMC neurons. Fig. 5 , right panel shows CA2 pyramidal neurones. The immunosignal, for all three antibodies, was confined to the cell bodies and apical dendrites in the control specimen. In the TLE-HS hippocampi there was neuronal loss. Furthermore the remaining neurones appeared smaller and contracted and the immunosignal seemed stronger in the cytoplasmic membrane. Fig. 6 , left panel displays pyramidal neurones in CA3. Immunopositivity was mainly confined to the neuronal bodies with almost no apical dendrites being immunolabelled with any of three antibodies in the PMC hippocampus. In TLE-HS neuronal loss was evident, the cells appeared to be smaller, and the immunoreactivity was present on the cytoplasmic membrane. There was also an apparent proliferation of glial cells as reported in literature (Charles et al., 2003; Kim et al., 1990; de Lanerolle et al., 2012) . The right panel of Fig. 6 exhibits DG granular cells at higher magnification. In the PMC specimen the immunoreactivity with all three antibodies was present exclusively in the cell somata. In TLE-HS sections neuronal loss was evident, in addition the granule cells were smaller and more dispersed, and immunolabelling was more intense.
Most of the pyramidal neurons in CAs areas and granule cells in DG were immunopositive. In addition, supported by recent evidence (Huyghe et al., 2014) , some interneurons and possibly some astrocytes appeared immunopositive to the GABA B antibodies. It would be appropriate in future to perform double fluorescent immunostaining to verify which subpopulation of neurons and glia express GABA B receptors.
Discussion
Previous studies have indicated that changes in the GABA B receptors subunits could be implicated in the pathophysiology of pharmaco-resistant TLE associated with HS (Billinton et al., 2001; Fürtinger et al., 2003b; Princivalle et al., 2003) . Therefore, studying GABA B receptor protein expression may provide an important contribution to our understanding of one of the most important mechanisms implicated in temporal lobe epilepsy.
The qRT-PCR results obtained in this study showed that there is no major difference in GABA B expression between TLE-HS and PMC samples. This is in agreement with previous data (Billinton et al., 2001) . In contrast, the TLE-STG samples demonstrated a higher expression of both subunits compared to TLE-HS and PMC samples. The quantitative Western blot perfectly mirrored the trend of PCR data for GABA B2 , but not for GABA B1. Figs. 1 and 2 clearly demonstrate that the GABA B2 subunit expression is significantly lower in TLE-HS samples compared to the bioptic TLE-STG, and higher compared to the PMC as well as the IHC shows. It is difficult to compare qRT-PCR GABA B2 mRNA to previous in situ hybridization data Fürtinger et al., 2003b) . However, overall both techniques indicate a higher expression of GABA B2 mRNAs in the epileptic hippocampi compared to the PMC control.
The protein quantification obtained from qWB demonstrated that GABA B1 and GABA B2 expression mirror the mRNA level in TLE-HS and TLE-STG. Visual comparison of the three proteins by IHC between PMC control and TLE-HS patients displayed a wide distribution of GABA B isoforms and subunits in both types of specimen. However, as previously reported Fürtinger et al., 2003b) , the quantitative comparison showed that, despite neuronal loss in TLE-HS hippocampal samples, there was an increment of GABA B1b and GABA B2 protein expression per remaining neuron in the CA areas and DG, compared to the PMC samples.
It may be argued that our findings are contradictory because the quantification of Western blot and IHC showed opposite trend for GABA B1a . However, it is important to point out that WB data represents the total GABA B1a expression as we used homogenates of hippocampal tissue containing neurones, microglia and astrocytes rather than just the neuronal portion. In contrast, the quantitative IHC data represent GABA B1a expression per neurone. Comparing the mRNA and protein expression in Figs. 1 and 2 , it is evident that the trend of the receptor subunits is the same, demonstrating that GABA B2 expression is very much lower in the hippocampi of pharmaco-resistant patients compared to TLE-STG. Previous binding and present immunohistochemical data in human hippocampal PMC control and epileptic specimens appear in reasonable agreement (Princivalle et al., 2002) .
In the IHC the higher expression of GABA B1b and GABA B2 in the surviving neurones of the DG reflects the mRNA per neurone levels reported elsewhere Fürtinger et al., 2003b) . In addition, the GABA B receptor autoradiography binding assays, corrected for neuronal loss Princivalle et al., 2002) , showed a significant increase in receptor density per neurone in specific hippocampal subregions of the TLE-HS compared to PMC samples.
The lower expression of both GABA B receptor subunits in TLE-HS compared to TLE-STG, could indicate a decline in GABA B receptors which would provide an explanation for the compromised GABA B functionality previously reported in pharmacological and electrophysiological studies in animal model and in human TLE Princivalle et al., 2002; Fürtinger et al., 2003b; Mare s and Kubov a, 2015; Leung et al., 2016; Rocha et al., 2015; Sun et al., 2016) . This may be affecting the formation of fully functional GABA B receptors: since the heterodimerisation of GABA B1 and GABA B2 in 1:1 stoichiometry is essential for receptor trafficking and G-protein activation, the GABA B2 subunit could be a potential target for the development of new agonists or activating transcription factors drugs, which may have a major clinical impact on the treatment of pharmaco-resistant TLE-HS patients. However, there are other factors which could explain the reduced GABAergic inhibition (Gill et al., 2010; Armstrong et al., 2016) , and there is a strong possibility of co-causation.
The findings of this study could be interpreted in two different ways: GABA B protein expression in epileptogenic hippocampal tissue could be down-regulated (because of the higher expression in TLE-STG tissue) or it could be up-regulated (because of the lower expression in PMC tissue). The decision which explanation is more likely depends on the relative merits of the two non-epileptogenic "control"-tissues. Unfortunately, neither PMC nor non-spiking TLE-STG is a perfect match for the TLE-HS samples of interest for the kind of experiments conducted here. However, there is no real alternative in human studies and it is not the first time that neocortex (STG) has been used in studies on TLE (Teichgr€ aber et al., 2009; Rocha et al., 2015) . Even human non-epileptogenic hippocampi removed for other reasons (such as temporal lobe tumours) cannot be considered an ideal control tissue for TLE-HS samples (Kov acs et al., 2012) . Son et al. (2015) demonstrated that tissue surrounding or adjacent to a tumour is physiologically and molecularly perturbed by the tumour itself or by previous irradiation.
In view of these difficulties, many studies investigating TLE pathophysiology have recently compared their results obtained in epileptogenic TLE specimens to other surgically resected samples such as neocortex. The strength of this approach includes the fact that both sample types contain the same DNA (reducing the risk of intersubjective variability caused by gene-gene or geneenvironment interactions) and that both samples were obtained and processed in the same way. This approach also avoids the difficulties associated with comparing TLE-HS tissue removed during epilepsy surgery with PMC-HS tissue possibly affected by an agonal state and post-mortem changes (Preece and Cairns, 2003; Tomita et al., 2004; Teichgr€ aber et al., 2009; Rocha et al., 2015) .
In this study, the expression of mature GABA B receptor proteins was investigated for the first time in TLE-HS, and in both types of "control" tissues, surgically resected non-spiking TLE-STG and PMC specimens.
Conclusions
In agreement with older studies, we found a statistically significant increase in overall expression of GABA B receptor protein in TLE-HS versus PMC. This finding suggests that the previously reported reduction in slow IPSPs in TLE-HS cannot be explained by a decreased protein expression of the GABA B receptor subunit. Instead this neurophysiological observation could be due to other causes including post-translational modification of the GABA B protein. On the other hand, this study shows a statistically significant lower expression of GABA B2 in TLE-HS samples than in nonepileptogenic TLE-STG from the same patients. Considering that the PMC values were affected by agonal or post-mortem changes (or due to undetected differences in clinical or demographic factors between TLE-HS and PMC subjects) the TLE-STG samples may represent a more appropriate "control" tissue. Therefore, the downregulation of GABA B2 transcription and GABA B2 mature protein subunit in TLE-HS could represent one of the reasons for the impaired GABAergic inhibition reported in epileptogenic hippocampal tissue in the literature.
